Hims & Hers Health (NYSE:HIMS) CFO Sells $505,973.89 in Stock

Key Points

• Hims & Hers Health CFO Oluyemi Okupe sold 11,581 shares of the company's stock for a total of $505,973.89, reducing his ownership by 9.02% to approximately 116,806 shares.
• The company's stock traded at $44.17 with a market cap of $9.98 billion, and had a significant trading volume of 17,737,994 shares.
• Hims & Hers Health reported $0.17 earnings per share for its last quarter, missing estimates, despite a 72.6% year-over-year revenue increase to $544.83 million.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 11,581 shares of the company's stock in a transaction on Tuesday, August 26th. The shares were sold at an average price of $43.69, for a total value of $505,973.89. Following the completion of the transaction, the chief financial officer directly owned 116,806 shares in the company, valued at approximately $5,103,254.14. This represents a 9.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, July 14th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $47.70, for a total value of $552,413.70.
• On Monday, July 7th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $46.67, for a total value of $540,485.27.
• On Monday, June 23rd, Oluyemi Okupe sold 23,107 shares of Hims & Hers Health stock. The stock was sold at an average price of $47.25, for a total value of $1,091,805.75.

Hims & Hers Health Trading Up 0.4%

Hims & Hers Health stock traded up $0.16 during trading hours on Thursday, hitting $44.17. The stock had a trading volume of 17,737,994 shares, compared to its average volume of 33,421,230. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The stock has a market cap of $9.98 billion, a price-to-earnings ratio of 55.21, a P/E/G ratio of 3.06 and a beta of 2.08. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98. The business's 50 day simple moving average is $50.76 and its 200-day simple moving average is $45.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company's quarterly revenue was up 72.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in the company. Thrivent Financial for Lutherans grew its stake in Hims & Hers Health by 3.6% in the second quarter. Thrivent Financial for Lutherans now owns 46,444 shares of the company's stock valued at $2,315,000 after acquiring an additional 1,617 shares during the period. Marex Group plc acquired a new stake in Hims & Hers Health in the second quarter valued at approximately $53,626,000. Nomura Holdings Inc. grew its stake in Hims & Hers Health by 151.4% in the second quarter. Nomura Holdings Inc. now owns 161,052 shares of the company's stock valued at $8,028,000 after acquiring an additional 96,997 shares during the period. Castleark Management LLC acquired a new stake in Hims & Hers Health in the second quarter valued at approximately $2,921,000. Finally, Tower Research Capital LLC TRC grew its stake in Hims & Hers Health by 54.3% in the second quarter. Tower Research Capital LLC TRC now owns 38,285 shares of the company's stock valued at $1,909,000 after acquiring an additional 13,473 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on HIMS shares. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Morgan Stanley reissued an "equal weight" rating and issued a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Piper Sandler reissued a "neutral" rating and issued a $39.00 price target (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Truist Financial decreased their target price on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research note on Monday, August 18th. Finally, Zacks Research cut Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Reduce" and an average price target of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.